Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,152
  • Shares Outstanding, K 39,620
  • Annual Sales, $ 490 K
  • Annual Income, $ -51,420 K
  • EBIT $ -70 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.32
  • Price/Sales 48.29
  • Price/Cash Flow N/A
  • Price/Book 0.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.54 on 11/13/25
  • Next Earnings Date 06/16/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 380.85% (+121.20%)
  • Historical Volatility 81.45%
  • IV Percentile 92%
  • IV Rank 68.99%
  • IV High 518.95% on 11/20/25
  • IV Low 73.56% on 08/01/25
  • Expected Move (DTE 26) 0.1700 (30.41%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 722
  • Volume Avg (30-Day) 714
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 21,882
  • Open Int (30-Day) 14,397
  • Expected Range 0.3891 to 0.7291

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.47
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +2.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4300 +30.02%
on 02/13/26
0.6808 -17.88%
on 01/22/26
-0.0861 (-13.34%)
since 01/20/26
3-Month
0.4300 +30.02%
on 02/13/26
5.1400 -89.12%
on 11/24/25
-3.8909 (-87.44%)
since 11/20/25
52-Week
0.4300 +30.02%
on 02/13/26
5.1400 -89.12%
on 11/24/25
-2.3109 (-80.52%)
since 02/20/25

Most Recent Stories

More News
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options

VTGN : 0.5591 (-5.61%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTGN

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN).  ...

VTGN : 0.5591 (-5.61%)
Shareholders that lost money on Vistagen Therapeutics, Inc.(VTGN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN).

VTGN : 0.5591 (-5.61%)
LEVI & KORSINSKY, LLP: VISTAGEN THERAPEUTICS STOCK DROPS OVER 80% FOLLOWING CLINICAL TRIAL DISCLOSURE -- CLASS ACTION SEEKS DAMAGES FOR INVESTORS

NEW YORK , Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) securities of the important March 16, 2026 lead plaintiff deadline....

VTGN : 0.5591 (-5.61%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- 

VTGN : 0.5591 (-5.61%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , Feb. 17, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ...

VTGN : 0.5591 (-5.61%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 17, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics,...

VTGN : 0.5591 (-5.61%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 13, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics,...

VTGN : 0.5591 (-5.61%)
Vistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGN

LOS ANGELES , Feb. 13, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN...

VTGN : 0.5591 (-5.61%)
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Feb. 13, 2026 /PRNewswire/ --

VTGN : 0.5591 (-5.61%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.6358
2nd Resistance Point 0.6188
1st Resistance Point 0.5890
Last Price 0.5591
1st Support Level 0.5422
2nd Support Level 0.5252
3rd Support Level 0.4954

See More

52-Week High 5.1400
Fibonacci 61.8% 3.3408
Fibonacci 50% 2.7850
Fibonacci 38.2% 2.2292
Last Price 0.5591
52-Week Low 0.4300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar